CU20160141A7 - DERIVED FROM BENZODIAZEPINA WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM - Google Patents

DERIVED FROM BENZODIAZEPINA WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM

Info

Publication number
CU20160141A7
CU20160141A7 CUP2016000141A CU20160141A CU20160141A7 CU 20160141 A7 CU20160141 A7 CU 20160141A7 CU P2016000141 A CUP2016000141 A CU P2016000141A CU 20160141 A CU20160141 A CU 20160141A CU 20160141 A7 CU20160141 A7 CU 20160141A7
Authority
CU
Cuba
Prior art keywords
central
nervous system
diseases
benzodiazepina
activity
Prior art date
Application number
CUP2016000141A
Other languages
Spanish (es)
Inventor
Fernández Pedro Gilberto Bárzaga
Hernández René Delgado
Fonseca Luis Arturo Fonseca
Suárez Bárbara Beatriz Garrido
Alfonso Nicté González
Figueredo Yanier Nuñez
Rodríguez Estael Ochoa
Yaquis Alejandro Saúl Padrón
Andreu Gilberto Lázaro Pardo
Sánchez Jeney Ramírez
Reyes Yamila Verdecia
Guerra Maylin Wong
Original Assignee
Centro De Investig Y Desarrollo De Medicamentos Cidem Organizacion Superior De Direccion Empresarial
Facultad De Quimica Univ De La Habana Ministerio De Educacion Superior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y Desarrollo De Medicamentos Cidem Organizacion Superior De Direccion Empresarial, Facultad De Quimica Univ De La Habana Ministerio De Educacion Superior filed Critical Centro De Investig Y Desarrollo De Medicamentos Cidem Organizacion Superior De Direccion Empresarial
Priority to CUP2016000141A priority Critical patent/CU20160141A7/en
Publication of CU20160141A7 publication Critical patent/CU20160141A7/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>Compuesto de formula III, sus derivados y composiciones farmacéuticas que los contienen para el tratamiento de enfermedades del sistema nervioso central y vascular, especialmente trastornos neurodegenerativos, con deterioro cognitivo, enfermedades asociadas al estrés oxidativo, enfermedades que cursan con disfunción mitocondrial, enfermedad de Parkinson y dolor neuropático, así como procesos patológicos asociadas con el envejecimiento. ESPACIO PARA FÓRMULA</p><p> Compound of formula III, its derivatives and pharmaceutical compositions containing them for the treatment of diseases of the central and vascular nervous system, especially neurodegenerative disorders, with cognitive impairment, diseases associated with oxidative stress, diseases that occur with mitochondrial dysfunction, disease of Parkinson's and neuropathic pain, as well as pathological processes associated with aging. FORMULA SPACE </p>

CUP2016000141A 2016-09-27 2016-09-27 DERIVED FROM BENZODIAZEPINA WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM CU20160141A7 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CUP2016000141A CU20160141A7 (en) 2016-09-27 2016-09-27 DERIVED FROM BENZODIAZEPINA WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2016000141A CU20160141A7 (en) 2016-09-27 2016-09-27 DERIVED FROM BENZODIAZEPINA WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM

Publications (1)

Publication Number Publication Date
CU20160141A7 true CU20160141A7 (en) 2018-05-08

Family

ID=62104051

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2016000141A CU20160141A7 (en) 2016-09-27 2016-09-27 DERIVED FROM BENZODIAZEPINA WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM

Country Status (1)

Country Link
CU (1) CU20160141A7 (en)

Similar Documents

Publication Publication Date Title
CL2018002505A1 (en) Wdr5 protein-protein aging inhibitors
CO2019000386A2 (en) Heterocyclic compounds as immunomodulators
CL2018003050A1 (en) Isoquinolin-3-yl-carboxamides, and preparation and use thereof.
CU20190073A7 (en) 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES
NI201600164A (en) COMPOUNDS AND COMPOSITIONS AS AGONISTS OF THE TOLL 7 TYPE RECEPTOR
NI201800124A (en) 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES
CL2018000375A1 (en) 2-amino-3-fluoro-3- (fluoromethyl) -6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors.
BR112016025048A2 (en) compounds and compositions as toll7 receptor agonists
CO2019012767A2 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compound
CO2017005959A2 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
CL2019002583A1 (en) Dual inhibitors of magl and faah.
CL2016002615A1 (en) Heterocyclyl sulfones substituted with heteroaryl and their use against pain, stroke, mood disorders, epilepsy, schizophrenia and neurodegenerative disorders.
CL2021001198A1 (en) Heteroaromatic compounds as vanine inhibitors
MX2020004666A (en) PILOCARPINE COMPOUNDS WITH LIPOIC ACID FOR THE TREATMENT OF OCULAR DISORDERS.
ECSP19026702A (en) NOVELTY COMPOUNDS FOR THE TREATMENT OF PARASITIC DISEASES
MX2018001592A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISORDERS.
CL2018001631A1 (en) Alkyl dihydroquinolinsulfonamide compounds
CO2021007442A2 (en) Composed of 1,3,4-oxadiazolone and drug
CU20160058A7 (en) DERIVED FROM BENZODIAZEPINA WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM
CU20160141A7 (en) DERIVED FROM BENZODIAZEPINA WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM
CO2020001375A2 (en) Adamantylmethylamine derivative and its use as a pharmaceutical product
EA201991835A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamides for the treatment of malignant neoplasms
CR20190028A (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
BR112017014226A2 (en) heterocyclylalkine derivatives and their use as mglur5 receptor modulators